PDS Biotechnology Corporation
General ticker "PDSB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $52.6M (TTM average)
PDS Biotechnology Corporation does not follow the US Stock Market performance with the rate: -15.8%.
Estimated limits based on current volatility of 7.9%: low 1.18$, high 1.38$
Factors to consider:
- Total employees count: 25 as of 2023
- Top business risk factors: Dependence on key products, Limited operating history, Significant losses, Need for additional capital, Regulatory and compliance
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.56$, 2.62$]
- 2026-12-31 to 2027-12-31 estimated range: [0.67$, 2.86$]
Financial Metrics affecting the PDSB estimates:
- Positive: with PPE of -1.1 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -69697.75 <= 0.07
- Positive: 19.49 < Shareholder equity ratio, % of 30.34 <= 42.60
- Positive: Investing cash flow per share per price, % of 0 > -0.65
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Inventory ratio change, % of 0 <= 0
Short-term PDSB quotes
Long-term PDSB plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $43.05MM | $36.32MM | $31.54MM |
| Operating Income | $-43.05MM | $-36.32MM | $-31.54MM |
| Non-Operating Income | $-1.30MM | $-2.16MM | $-4.12MM |
| Interest Expense | $5.51MM | $4.67MM | $5.34MM |
| R&D Expense | $27.76MM | $22.57MM | $19.03MM |
| Income(Loss) | $-44.35MM | $-38.48MM | $-35.67MM |
| Taxes | $-1.41MM | $-0.87MM | $-1.17MM |
| Profit(Loss)* | $-42.94MM | $-37.61MM | $34,426.51MM |
| Stockholders Equity | $26.13MM | $19.00MM | $9.25MM |
| Assets | $59.39MM | $45.36MM | $30.49MM |
| Operating Cash Flow | $-33.64MM | $-35.03MM | $-27,752.01MM |
| Capital expenditure | $0.00MM | $0.03MM | $0.00MM |
| Investing Cash Flow | $0.00MM | $-0.03MM | $0.00MM |
| Financing Cash Flow | $16.38MM | $20.19MM | $12,774.39MM |
| Earnings Per Share** | $-1.39 | $-1.03 | $742.20 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.